Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Neuropharmacology of halogenated DMT analogs: psychoplastogenic and antidepressant properties of 5-Br-DMT, a psychedelic derivative with low hallucinogenic potential

  • Puigseslloses, Pol
  • Nadal-Gratacós, Núria
  • Fumas, Berta
  • Modenutti, Carlos Pablo
  • Pottie , Eline
  • Ortigosa, Juan Rodrigo
  • Pablo-Quesada, Albert
  • Riera Colomer, Clara
  • Ettcheto, Miren
  • Berzosa, Xavier
  • Pubill, David
  • Stove, Christophe
  • Escubedo, Elena
  • López-Arnau, Raúl
Current first-line antidepressants, such as selective serotonin reuptake inhibitors (SSRI), often present a delayed onset of action and fail to effectively treat a large proportion of patients, leaving a gap in the treatment of mood disorders. Psychedelics have recently emerged as promising alternatives due to their ability to produce fast-acting antidepressant effects through neuroplastic adaptations, but their hallucinogenic properties remain a major obstacle to their widespread therapeutic use. In this study, we characterized a novel class of halogenated DMT derivatives—5-F-DMT, 5-Cl-DMT, and 5-Br-DMT—for their pharmacological activity, behavioral effects, and therapeutic potential. Using a combination of in vitro assays, in silico modeling, and in vivo behavioral and gene expression studies, we found that halogen substitution at the 5-position modulates receptor affinity and selectivity across key serotonin (5-HT) receptors (5-HT1A/2 A/2B/2CR) and transporter (SERT). Notably, 5-Br-DMT was found to activate 5-HT2AR but did not induce the head twitch response (HTR) in mice, suggesting non-hallucinogenic activity. Furthermore, 5-Br-DMT upregulated immediate early genes (IEGs) associated with neuroplasticity in the mouse prefrontal cortex and hippocampus (Arc, Egr-1, -2 and -3) and promoted dendritic growth in cortical neurons. In a mouse model of stress-induced depression, a single administration (10 mg/kg, i.p.) of 5-Br-DMT resulted in a significant reduction in depressive-like behavior, reflecting rapid antidepressant effects. Collectively, our results highlight 5-Br-DMT as a non-hallucinogenic psychoplastogen with antidepressant properties, supporting its potential as a prototypical candidate for further study. Moreover, the evaluation and biological characterization of the halogenated DMT derivatives offers valuable information on structure-activity relationships that may guide the design of future therapeutic compounds., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Pharmacological characterization of 4-F-3-Me-α-PVP: A novel synthetic cathinone with psychostimulant effects and abuse liability in rodents

  • Nadal-Gratacós, Núria
  • Pain, Stephanie
  • Mata, Sandra
  • Puigseslloses, Pol
  • De Macedo, Morgane
  • Lardeux, Virginie
  • WANG, Fu-Hua
  • Källsten, Liselott
  • Pubill, David
  • Berzosa, Xavier
  • Kehr, Jan
  • Solinas, Marcello
  • Escubedo, Elena
  • Camarasa, Jordi
  • López-Arnau, Raúl
Background: The continual emergence of novel synthetic cathinones poses significant public health concerns due to their unpredictable pharmacological profiles and potential for abuse. Among these, 4-F-3-Me-α-PVP—a newly identified analogue of α-PVP—has recently surfaced on the illicit drug market, yet its biological effects remain uncharacterized. Aim: To provide the first comprehensive pharmacological evaluation of 4-F-3-Me-α-PVP. Methods: In vitro transporter inhibition was assessed using HEK293 cells expressing human dopamine (DA), norepinephrine, and serotonin transporter (DAT, NET, or SERT). In male rodents, locomotor activity was measured after i.p. (mice) or s.c. (rats) administration. In vivo microdialysis in rats quantified extracellular DA in the nucleus accumbens. Rewarding and reinforcing effects were evaluated using conditioned place preference (CPP) in mice and intravenous self-administration (IVSA) in rats under fixed-ratio and progressive-ratio schedules. Results: In vitro assays revealed that 4-F-3-Me-α-PVP acts as a potent DAT and NET inhibitor, with additional, though weaker, activity at SERT. In vivo, 4-F-3-Me-α-PVP significantly increased locomotor activity in male rodents (10 and 30 mg/kg in mice; 3 mg/kg in rats). Importantly, 4-F-3-Me-α-PVP also increased extracellular DA levels in the rat nucleus accumbens (3 mg/kg, s.c.), pointing to its potential for abuse. Behavioral assays further demonstrated rewarding and reinforcing effects in rodents, with significant CPP in mice at all doses tested and dose-dependent IVSA in rats observed under both fixed-ratio and progressive-ratio schedules. Conclusions: Collectively, these findings indicate that 4-F-3-Me-α-PVP possesses substantial psychostimulant and abuse-related effects in rodents, underscoring the need for regulatory vigilance and continued investigation into emerging synthetic cathinones., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

The psychedelic phenethylamine 25C-NBF, a selective 5-HT2A agonist, shows psychoplastogenic properties and rapid antidepressant effects in male rodents

  • Nadal-Gratacós, Núria
  • Puigseslloses, Pol
  • Guzmán, Laura
  • Weiss, Nicola
  • Pottie , Eline
  • Riera Colomer, Clara
  • Lardeux, Virginie
  • THIRIET, Nathalie
  • Wang, Fu-Hua
  • Källsten, Liselott
  • Pérez-Esteban, Irene
  • Ketsela, Gabriel
  • Margall, Joel
  • Berzosa, Xavier
  • Pubill, David
  • Rodríguez-Arias, Marta
  • Ettcheto, Miren
  • Kehr, Jan
  • Stove, Christophe
  • Solinas, Marcello
  • Sitte, Harald
  • Escubedo, Elena
  • López-Arnau, Raúl
Psychedelics have garnered significant interest for their therapeutic potential in mental health conditions such as depression, anxiety, and post-traumatic stress disorder. While research has primarily focused on well-studied psychedelics, phenethylamine derivatives have also gathered interest for their potential therapeutic applications. Thus, this study aims to investigate the pharmacological profile, safety and therapeutic potential of novel N-(2-fluorobenzyl) phenethylamine analogs (NBFs) of the 2C-X series—25C-NBF, 25B-NBF, and 25I-NBF. NBFs displayed high affinity and selectivity for the 5-HT2A receptor and demonstrated bias factors (defined in our study as the preference for Gq over β-arrestin pathways at 5-HT2A receptor) similar to that of 5-HT. Acute administration induced moderate head-twitch responses without affecting locomotion or pre-pulse inhibition. Our studies revealed no rewarding effects in mice nor reinforcing effects or changes in accumbal dopamine levels in rats after NBFs administration. Further characterization of 25C-NBF revealed psychoplastogenic effects (dendritogenesis, spinogenesis and increased Bdnf mRNA levels) both in vitro and in vivo. In addition, 25C-NBF reduced despair-like behavior in response to acute stress and exerted rapid antidepressant effects in a model of anhedonia-like behavior induced by chronic corticosterone administration. Taken together, these findings suggest that 25C-NBF, and further analogs, may hold potential as novel antidepressants with a rapid onset of action and a favorable safety profile in terms of no abuse potential or sensorimotor gating deficits., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The psychedelic phenethylamine 25C-NBF, a selective 5-HT2A agonist, shows psychoplastogenic properties and rapid antidepressant effects in male rodents

  • Nadal-Gratacós, Núria
  • Puigseslloses, Pol
  • Guzmán, Laura
  • Weiss, Nicola
  • Pottie , Eline
  • Riera Colomer, Clara
  • Lardeux, Virginie
  • THIRIET, Nathalie
  • Wang, Fu-Hua
  • Källsten, Liselott
  • Pérez-Esteban, Irene
  • Ketsela, Gabriel
  • Margall, Joel
  • Berzosa, Xavier
  • Pubill, David
  • Rodríguez-Arias, Marta
  • Ettcheto, Miren
  • Kehr, Jan
  • Stove, Christophe
  • Solinas, Marcello
  • Sitte, Harald
  • Escubedo, Elena
  • López-Arnau, Raúl
Psychedelics have garnered significant interest for their therapeutic potential in mental health conditions such as depression, anxiety, and post-traumatic stress disorder. While research has primarily focused on well-studied psychedelics, phenethylamine derivatives have also gathered interest for their potential therapeutic applications. Thus, this study aims to investigate the pharmacological profile, safety and therapeutic potential of novel N-(2-fluorobenzyl) phenethylamine analogs (NBFs) of the 2C-X series—25C-NBF, 25B-NBF, and 25I-NBF. NBFs displayed high affinity and selectivity for the 5-HT2A receptor and demonstrated bias factors (defined in our study as the preference for Gq over β-arrestin pathways at 5-HT2A receptor) similar to that of 5-HT. Acute administration induced moderate head-twitch responses without affecting locomotion or pre-pulse inhibition. Our studies revealed no rewarding effects in mice nor reinforcing effects or changes in accumbal dopamine levels in rats after NBFs administration. Further characterization of 25C-NBF revealed psychoplastogenic effects (dendritogenesis, spinogenesis and increased Bdnf mRNA levels) both in vitro and in vivo. In addition, 25C-NBF reduced despair-like behavior in response to acute stress and exerted rapid antidepressant effects in a model of anhedonia-like behavior induced by chronic corticosterone administration. Taken together, these findings suggest that 25C-NBF, and further analogs, may hold potential as novel antidepressants with a rapid onset of action and a favorable safety profile in terms of no abuse potential or sensorimotor gating deficits., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Neuropharmacology of halogenated DMT analogs: psychoplastogenic and antidepressant properties of 5-Br-DMT, a psychedelic derivative with low hallucinogenic potential

  • Puigseslloses, Pol
  • Nadal-Gratacós, Núria
  • Fumas, Berta
  • Modenutti, Carlos Pablo
  • Pottie , Eline
  • Ortigosa, Juan Rodrigo
  • Pablo-Quesada, Albert
  • Riera Colomer, Clara
  • Ettcheto, Miren
  • Berzosa, Xavier
  • Pubill, David
  • Stove, Christophe
  • Escubedo, Elena
  • López-Arnau, Raúl
Current first-line antidepressants, such as selective serotonin reuptake inhibitors (SSRI), often present a delayed onset of action and fail to effectively treat a large proportion of patients, leaving a gap in the treatment of mood disorders. Psychedelics have recently emerged as promising alternatives due to their ability to produce fast-acting antidepressant effects through neuroplastic adaptations, but their hallucinogenic properties remain a major obstacle to their widespread therapeutic use. In this study, we characterized a novel class of halogenated DMT derivatives—5-F-DMT, 5-Cl-DMT, and 5-Br-DMT—for their pharmacological activity, behavioral effects, and therapeutic potential. Using a combination of in vitro assays, in silico modeling, and in vivo behavioral and gene expression studies, we found that halogen substitution at the 5-position modulates receptor affinity and selectivity across key serotonin (5-HT) receptors (5-HT1A/2 A/2B/2CR) and transporter (SERT). Notably, 5-Br-DMT was found to activate 5-HT2AR but did not induce the head twitch response (HTR) in mice, suggesting non-hallucinogenic activity. Furthermore, 5-Br-DMT upregulated immediate early genes (IEGs) associated with neuroplasticity in the mouse prefrontal cortex and hippocampus (Arc, Egr-1, -2 and -3) and promoted dendritic growth in cortical neurons. In a mouse model of stress-induced depression, a single administration (10 mg/kg, i.p.) of 5-Br-DMT resulted in a significant reduction in depressive-like behavior, reflecting rapid antidepressant effects. Collectively, our results highlight 5-Br-DMT as a non-hallucinogenic psychoplastogen with antidepressant properties, supporting its potential as a prototypical candidate for further study. Moreover, the evaluation and biological characterization of the halogenated DMT derivatives offers valuable information on structure-activity relationships that may guide the design of future therapeutic compounds., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Pharmacological characterization of 4-F-3-Me-α-PVP: A novel synthetic cathinone with psychostimulant effects and abuse liability in rodents

  • Nadal-Gratacós, Núria
  • Pain, Stephanie
  • Mata, Sandra
  • Puigseslloses, Pol
  • De Macedo, Morgane
  • Lardeux, Virginie
  • WANG, Fu-Hua
  • Källsten, Liselott
  • Pubill, David
  • Berzosa, Xavier
  • Kehr, Jan
  • Solinas, Marcello
  • Escubedo, Elena
  • Camarasa, Jordi
  • López-Arnau, Raúl
Background: The continual emergence of novel synthetic cathinones poses significant public health concerns due to their unpredictable pharmacological profiles and potential for abuse. Among these, 4-F-3-Me-α-PVP—a newly identified analogue of α-PVP—has recently surfaced on the illicit drug market, yet its biological effects remain uncharacterized. Aim: To provide the first comprehensive pharmacological evaluation of 4-F-3-Me-α-PVP. Methods: In vitro transporter inhibition was assessed using HEK293 cells expressing human dopamine (DA), norepinephrine, and serotonin transporter (DAT, NET, or SERT). In male rodents, locomotor activity was measured after i.p. (mice) or s.c. (rats) administration. In vivo microdialysis in rats quantified extracellular DA in the nucleus accumbens. Rewarding and reinforcing effects were evaluated using conditioned place preference (CPP) in mice and intravenous self-administration (IVSA) in rats under fixed-ratio and progressive-ratio schedules. Results: In vitro assays revealed that 4-F-3-Me-α-PVP acts as a potent DAT and NET inhibitor, with additional, though weaker, activity at SERT. In vivo, 4-F-3-Me-α-PVP significantly increased locomotor activity in male rodents (10 and 30 mg/kg in mice; 3 mg/kg in rats). Importantly, 4-F-3-Me-α-PVP also increased extracellular DA levels in the rat nucleus accumbens (3 mg/kg, s.c.), pointing to its potential for abuse. Behavioral assays further demonstrated rewarding and reinforcing effects in rodents, with significant CPP in mice at all doses tested and dose-dependent IVSA in rats observed under both fixed-ratio and progressive-ratio schedules. Conclusions: Collectively, these findings indicate that 4-F-3-Me-α-PVP possesses substantial psychostimulant and abuse-related effects in rodents, underscoring the need for regulatory vigilance and continued investigation into emerging synthetic cathinones., info:eu-repo/semantics/publishedVersion